- Case Western Reserve University School of Law, J.D., 2000, magna cum laude, Order of the Coif
- The Ohio State University, B.A., 1996
Bar & Court Admissions
Matt is a partner in the Vorys Cleveland office and a member of the health care group. He advises in all areas of health care law, but focuses his practice on health care mergers and acquisitions activity.
Matt also has significant experience in the areas of clinical device and pharmaceutical research, NIH and industry grant funding, related intellectual property issues and the integration of the clinical and academic components of an academic medical center. In addition, Matt has represented clients in response to government investigations from the Office of Inspector General, Centers for Medicare & Medicaid Services, and the Food and Drug Administration.
Immediately prior to joining Vorys, Matt spent four years serving as an Associate General Counsel for University Hospitals Health System in Cleveland, specifically working with University Hospitals Case Medical Center, the tertiary/quaternary care academic medical center affiliated with Case Western Reserve University. Prior to his work at University Hospitals, Matt worked as a litigation and health care associate at Vorys.
Matt is a member of the American Health Lawyers Association, the Society of Ohio Healthcare Attorneys and the Healthcare Financial Management Association.
Matt received his J.D. magna cum laude from Case Western Reserve University School of Law, where he was a member of the order of the coif. He received a B.A. in Political Science from The Ohio State University.
Professional and Community Activities
- Friends of MC2Stem, Board Member, 2018
Honors & Awards
- Chambers and Partners, Leading Lawyer in Health Care, 2013-2018
- The Best Lawyers in America, Health Care Law, 2011-2019
- Ohio Super Lawyers Rising Stars, Health Care, 2012-2013
- 5/2/2017Whistleblower Defense Alert: The Third Circuit Confirms Broad Power of Escobar’s Materiality RequirementsOn May 1, 2017, the Third Circuit affirmed the dismissal of a False Claims Act (FCA) case in which the eelator had asserted that Genentech concealed information about side effects of its cancer drug, Avastin. U.S. ex rel. Petratos, v. Genentech Inc., et al., Case No. 15-3805 (3rd Cir. May 1, 2017).
- 12/19/2016Whistleblower Defense Alert: The Supreme Court Rejects Mandatory Dismissal of Relator Claims For Seal ViolationsOn December 6, 2016, the Supreme Court of the United States handed down their second unanimous interpretation of the contours of the False Claims Act (FCA) in the last six months.